“Increasing Autoimmune and Inflammatory Disease Cases”
The growing prevalence of autoimmune and inflammatory diseases, such as rheumatoid arthritis, psoriasis, and atopic dermatitis, is a significant trend driving the demand for JAK1 inhibitors. According to the Global Burden of Disease Study, the incidence of autoimmune conditions has risen globally, with rheumatoid arthritis affecting approximately 14 million people in 2023. This trend highlights the increasing recognition and diagnosis of such conditions, fueled by advancements in medical diagnostics and growing awareness among healthcare providers. For Instance, the rise in biologic therapies like JAK1 inhibitors demonstrates the industry's response to address unmet needs in managing these chronic conditions, further validating this driver.
